查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363926

全球子宫颈肌张力失调治疗市场 2023-2030

Global Cervical Dystonia Treatment Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

预计全球颈部肌张力失调治疗市场在预测期内将以 7.8% 的复合年增长率成长。颈部肌张力失调是一种神经系统疾病，会导致颈部肌肉不自主收缩。这可能会导致头部向一侧倾斜或扭曲，或下巴向上、向下、向前或向后拉。推动市场成长的主要因素包括颈部肌张力失调的盛行率不断增加。据国家罕见疾病组织 (NORD) 称，美国估计有 60,000 人患有颈部肌张力失调。此外，估计全球每 10 万人中有 5 至 30 例。由于这些因素，对颈部肌张力失调的有效治疗的需求显着增加。肉毒桿菌注射/药物被认为是最有效且耐受性良好的治疗方法。然而，新的和创新的治疗方法已经取得了一些进展，例如深部脑部刺激（DBS）、干细胞疗法、基因疗法等。

细分市场前景

全球颈部肌张力失调治疗市场根据药物类型、应用和最终用户类型进行细分。依药物类型，市场分为肉毒桿菌、抗胆碱能药物、多巴胺能药物等。根据应用，市场分为医院药局、零售药局、网路药局等。根据最终用户，市场分为医院、诊所和其他。在申请中，医院药局预计将占据相当大的市场份额，因为大多数用于治疗颈部肌张力失调的药物均未获授权销售。

肉毒桿菌毒素药物类型将主导全球子宫颈肌张力失调治疗市场

在药物类型中，肉毒桿菌细分市场预计将占据显着的市场份额。由于其高效性和安全性，它是治疗颈部肌张力失调最常用的药物。因此，全球范围内肉毒桿菌毒素药物的开发和审批活动持续稳定。例如，2021年，美国FDA批准了一种名为Daxxify的新型肉毒桿菌药物。它是一种更有效的肉毒桿菌毒素，已被证明比旧的肉毒桿菌毒素药物在治疗颈部肌张力失调方面更有效。此类批准活动将导致更多地采用肉毒毒素注射和药物作为颈部肌张力失调的有效治疗方法。

区域展望

全球颈部肌张力失调治疗市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（义大利、西班牙、德国、法国等）、亚太地区（印度、中国、日本、韩国、等）以及世界其他地区（中东、非洲和拉丁美洲）。其中，由于北美拥有完善的颈部肌张力失调治疗研究机构和医院，预计将主导市场。

欧洲地区将在全球子宫颈肌张力失调市场中占据显着份额

在所有地区中，预计欧洲地区将在全球颈部肌张力失调市场中占据相当大的份额。这一增长主要是由于该地区颈部肌张力失调盛行率上升。据英国肌张力失调组织称，最常见的肌张力失调是颈部肌张力失调，影响英国约 18,000 名成年人。因此，各种策略措施的采用显着增加，例如合作和合併等，以透过提供有效的治疗来减少整个地区颈部肌张力失调的数量。例如，2023 年 8 月，IPSEN 宣布与 Dystonia Europe 合作，协助发现颈部肌张力失调患者未满足的需求。该计画包括共同创建首个颈部肌张力失调患者体验图，该地图发表在《Orphanet 罕见疾病杂誌》上，该地图记录了英国、法国和义大利15 名颈肌肌张力失调患者从最初诊断到生活的经历。与日常的情况。

市场参与者展望

服务全球颈部肌张力失调治疗市场的主要公司包括艾伯维公司（AbbVie Inc.）、易普森製药公司（Ipsen Pharma）、Merz Pharma GmbH & Co.KGaA.、Revance Therapeutics, Inc.、Hint, Inc.和USWM, LLC 等。市场参与者透过各种策略（包括併购、合作、合作和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2023 年 8 月，美国食品药物管理局批准 Daxxify（DaxibotulinumtoxinA-lanm；Revance Therapeutics，纳许维尔，田纳西州）作为其第一个注射治疗适应症，用于治疗成人颈部肌张力失调。

报告涵盖：

  • 2022年市场价​​值资料分析及2030年预测。
  • 每个细分市场的年化市场收入（百万美元）。
  • 主要地理区域的国家分析。
  • 全球颈部肌张力失调治疗市场的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
  • 透过确定未来强劲成长的关键细分市场来分析业务策略。
  • 市场进入和市场扩张策略分析。
  • 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • AbbVie Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Ipsen Pharma
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Merz Pharma GmbH & Co.KGaA.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Revance Therapeutics, Inc., Hint, Inc.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • USWM, LLC
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按药物类型分類的全球子宫颈肌张力失调治疗市场
    • 肉毒桿菌毒素
    • 抗胆碱能药物
    • 多巴胺能药物
    • 其他的
  • 全球子宫颈肌张力失调治疗市场（按应用）
    • 医院药房
    • 零售药房
    • 网路药房
    • 其他（专营药局）
  • 全球子宫颈肌张力失调治疗市场（按最终用户）
    • 医院
    • 诊所
    • 其他（临床研究机构）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Addex Pharma SA
  • Akorn Inc
  • Almirall, S.A.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • BIOGEN INC.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • DAIICHI SANKYO Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Galderma S.A.
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co., Ltd.
  • Lannett Co., Inc.
  • Mylan Pharmaceutical Pvt. Ltd.
  • Novartis AG.
  • Pfizer Inc.
  • Piramal Grp.
  • SANOFI
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Ind., Ltd.
  • Teva Pharmaceutical Ind., Ltd.
  • UCB Biopharma SRL.
Product Code: OMR2027701

Title: Global Cervical Dystonia Treatment Market Size, Share & Trends Analysis Report Market by Drug Type (Botulinum toxin, Anticholinergic agents, Dopaminergic agents, and Others), by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and by End-User (Hospitals, Clinics, and Others)Forecast Period (2023-2030).

The global cervical dystonia treatment market is anticipated to grow at a considerable CAGR of 7.8% during the forecast period. Cervical dystonia is a neurological disorder that causes the muscles in the neck to contract involuntarily. This can cause the head to lean or twist to one side, or the chin to pull up, down, forward, or backward. Primary factor propelling the market growth includes the increasing prevalence of cervical dystonia. According to the National Organization for Rare Disorders, Inc. (NORD), an estimated 60,000 people in the US are suffering with cervical dystonia. Furthermore, the estimated prevalence ranges from 5 to 30 cases per 100,000 individuals around the globe. Owing to such factors, there is significant increase in the demand for effective treatments of cervical dystonia. Botulinum toxin injections/ medications are considered the most effective and well-tolerated treatment. However, there are several developments of new and innovative treatment such as deep brain stimulation (DBS), and stem cell therapy, gene therapy, among others.

Segmental Outlook

The global cervical dystonia treatment market is segmented based on drug type, application and end-user type. Based on drug type, the market is segmented into botulinum toxin, anticholinergic agents, dopaminergic agents, and others. Based on application, the market is sub-segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Based on end-user, the market is sub-segmented into hospitals, clinics and others. Among the application, the hospital pharmacy is expected to hold a considerable share of the market, as most of the drugs prescribed for the treatment of cervical dystonia are not authorized to sale such drugs.

Botulinum Toxin Drug Type to Dominate the Global Cervical Dystonia Treatment Market

Among the drug type, the botulinum toxin sub-segment is expected to hold a prominent share of the market. It is the most common type of drug used to treat cervical dystonia owing to its high efficacy and safety. Thus, there is continuous and steady development and approval activities for botulinum toxin drugs around the globe. For instance, in 2021, the US FDA approved a new botulinum toxin medication named Daxxify. It is a more potent botulinum toxin that has been shown to be more effective than older botulinum toxin medications in treating cervical dystonia. Such approval activities will lead to an increase in the adoption of botulinum toxin injections and medications as the effective treatment of cervical dystonia.

Regional outlooks

The global cervical dystonia treatment market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, North America is expected to dominate the market, owing to the presence of well-established research institutes and hospitals for treatment of cervical dystonia.

European Region to Hold a Prominent Share of the Global Cervical Dystonia Market

Among all regions, the European region is anticipated to hold a considerable share of the global cervical dystonia market. The growth is primarily owing to the rising prevalence of cervical dystonia in the region. According to the Dystonia UK Organization, the most common dystonia is the neck dystonia, which affects around 18,000 adults in the UK. Resultantly, there is a considerable increase in the adoption of various strategic initiatives such as collaborations and mergers, among others to reduce the number of cervical dystonia across the region by providing effective treatment. For instance, in August 2023, IPSEN announced its collaboration with Dystonia Europe to help uncover the unmet needs of people living with cervical dystonia. The project included the co-creation of the first ever cervical dystonia patient experience map, published in the Orphanet Journal of Rare Disease, which charted the experiences of 15 people living with cervical dystonia in the UK, France and Italy, from initial diagnosis to living with the condition day-to-day.

Market Players Outlook

The major companies serving the global cervical dystonia treatment market include AbbVie Inc., Ipsen Pharma, Merz Pharma GmbH & Co.KGaA., Revance Therapeutics, Inc., Hint, Inc., and USWM, LLC among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in August, 2023 , the Food and Drug Administration approved Daxxify (DaxibotulinumtoxinA-lanm; Revance Therapeutics, Nashville, TN) for its first therapeutic indication for injection to treat cervical dystonia in adults.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global cervical dystonia treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. AbbVie Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Ipsen Pharma
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Merz Pharma GmbH & Co.KGaA.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Revance Therapeutics, Inc., Hint, Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. USWM, LLC
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cervical Dystonia Treatment Market by Drug Type
    • 4.1.1. Botulinum Toxin
    • 4.1.2. Anticholinergic Agents
    • 4.1.3. Dopaminergic Agents
    • 4.1.4. Others
  • 4.2. Global Cervical Dystonia Treatment Market by Application
    • 4.2.1. Hospital Pharmacy
    • 4.2.2. Retail Pharmacy
    • 4.2.3. Online Pharmacy
    • 4.2.4. Others (Specialty Drug Stores)
  • 4.3. Global Cervical Dystonia Treatment Markey by End-User
    • 4.3.1. Hospitals
    • 4.3.2. Clinics
    • 4.3.3. Others (Clinical Research Organizations)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Addex Pharma SA
  • 6.2. Akorn Inc
  • 6.3. Almirall, S.A.
  • 6.4. Apotex Inc.
  • 6.5. Astellas Pharma Inc.
  • 6.6. BIOGEN INC.
  • 6.7. Boehringer Ingelheim International GmbH
  • 6.8. Bristol Myers Squibb Co.
  • 6.9. DAIICHI SANKYO Co., Ltd.
  • 6.10. Dr. Reddy's Laboratories Ltd.
  • 6.11. Eisai Co., Ltd.
  • 6.12. Galderma S.A.
  • 6.13. H. Lundbeck A/S
  • 6.14. Johnson & Johnson Services, Inc.
  • 6.15. Kyowa Kirin Co., Ltd.
  • 6.16. Lannett Co., Inc.
  • 6.17. Mylan Pharmaceutical Pvt. Ltd.
  • 6.18. Novartis AG.
  • 6.19. Pfizer Inc.
  • 6.20. Piramal Grp.
  • 6.21. SANOFI
  • 6.22. Sumitomo Pharma Co., Ltd.
  • 6.23. Sun Pharmaceutical Ind., Ltd.
  • 6.24. Teva Pharmaceutical Ind., Ltd.
  • 6.25. UCB Biopharma SRL.

LIST OF TABLES

  • 1. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL CERVICAL DYSTONIA BOTULINUM TOXIN TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL CERVICAL DYSTONIA ANTICHOLINERGIC AGENTS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL CERVICAL DYSTONIA DOPAMINERGIC AGENTS TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL OTHER TYPE OF CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 7. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITAL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL CERVICAL DYSTONIA TREATMENT FOR RETAIL PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CERVICAL DYSTONIA TREATMENT FOR ONLINE PHARMACY MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL CERVICAL DYSTONIA TREATMENT FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 20. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 24. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 28. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY DRUG TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL CERVICAL DYSTONIA BOTULINUM TOXIN TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL CERVICAL DYSTONIA ANTICHOLINERGIC AGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL CERVICAL DYSTONIA DOPAMINERGIC AGENTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL OTHER TYPE OF CERVICAL DYSTONIA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY APPLICATION, 2022 VS 2030 ($ MILLION)
  • 7. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITAL PHARMACY MARKET SHARE BY REGION, 2022 VS. 2030 (%)
  • 8. GLOBAL CERVICAL DYSTONIA TREATMENT FOR RETAIL PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CERVICAL DYSTONIA TREATMENT FOR ONLINE PHARMACY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY END-USER, 2022 VS 2030 ($ MILLION)
  • 12. GLOBAL CERVICAL DYSTONIA TREATMENT FOR HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CERVICAL DYSTONIA TREATMENT FOR CLINICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL CERVICAL DYSTONIA TREATMENT FOR OTHER MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CERVICAL DYSTONIA TREATMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. US CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. CANADA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. UK CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. FRANCE CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. GERMANY CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. ITALY CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SPAIN CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF EUROPE CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. INDIA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. CHINA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. JAPAN CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. SOUTH KOREA CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD CERVICAL DYSTONIA TREATMENT MARKET SIZE, 2022-2030 ($ MILLION)